Parker Petit, chairman and CEO of MiMedx, attributed the company’s success to various factors, including a greater-than-expected revenue from the amniotic membrane tissue product line. The company also received FDA clearance for the AmnioFix and EpiFix products in the amniotic membrane tissues line.
During the second quarter, the company consolidated operations and closed its Tampa, Fla., facility.
Read the release on MiMedx Group.
Related Articles on MiMedx Group:
MiMedx Receives FDA Clearance for HydroFix Vaso Shield
MiMedx Q1 Revenues Up Following Surgical Biologics Acquisition
MiMedx to Feature Two Spinal Surgery Products
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.